达格列酮
- CAS号:141200-24-0
- 英文名:darglitazone
- 中文名:达格列酮
- CBNumber:CB41382639
- 分子式:C23H20N2O4S
- 分子量:420.48
- MOL File:141200-24-0.mol
- 密度 :1.306±0.06 g/cm3(Predicted)
- 储存条件 :Store at -20°C
- 溶解度 :DMSO:20.0(Max Conc. mg/mL);47.56(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);47.56(Max Conc. mM) - 形态 :A crystalline solid
- 酸度系数(pKa) :6.22±0.50(Predicted)
- 颜色 :White to light yellow
达格列酮性质、用途与生产工艺
- 生物活性 Darglitazone (CP-86325),一种噻唑烷二酮,是一种有效的,选择性的和具有口服活性的 PPAR-γ 激动剂。Darglitazone 有效控制血糖和脂质代谢,可用于 II 型糖尿病研究。
-
靶点
PPAR-γ
-
体外研究
In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), within 4 h of exposing these cells to 30 μM Darglitazone, there is an increase in uncoupling protein 2 (UCP2) mRNA which reached a plateau of 5-10 times the basal in about 8 h. Darglitazone can stimulate the expression of UCP2 gene probably via PPAR-γ.
-
体内研究
Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24 h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult.
Animal Model: Male diabetic ob/ob mice Dosage: 1 mg/kg Administration: Oral administration; daily; for 7 days Result: Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice.
- 更新日期:2024/08/19
- 产品编号:HY-120160
- 产品名称:Darglitazone
- CAS编号:
- 包装:5 mg
- 价格:1100元
- 更新日期:2024/08/19
- 产品编号:HY-120160
- 产品名称:Darglitazone
- CAS编号:
- 包装:10 mg
- 价格:1800元
- 公司名称:CLEARSYNTH LABS LTD.
- 联系电话:--
- 电子邮件:sales@clearsynth.com
- 国家:印度
- 产品数:6351
- 优势度:58